LLY vs WVE: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

LLY is the larger of the two ($1.20T market cap): the incumbent the market prices for continued execution (26.59x forward earnings, beta 0.39). WVE is the smaller challenger ($521.67M), still expected to post a loss next year: more room to run, but more to prove. On the numbers, LLY leads on both counts: faster expected revenue growth (16% vs -45%) and expected profits next year, which WVE does not have. The case for WVE rests on its own driver (WVE-006 and the AATD registrational path): if you believe in that, WVE fits; if you believe in what the numbers show today, LLY does.

LLY vs WVE: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricLLYWVEWhat it tells you
Market cap$1.20T$521.67MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E26.59-2.22Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.39-1.44Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range80% of range0% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book29.931.30How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how LLY and WVE affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and WVE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and WVE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Eli Lilly (LLY) do?

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

What does Wave Life Sciences (WVE) do?

Wave Life Sciences builds oligonucleotide medicines, short synthetic strands of genetic material that silence, edit or splice RNA inside cells. Its PRISM platform spans GalNAc-siRNA (the SpiNA design), RNA editing (AIMers, which recruit the body's own ADAR enzymes to correct a single RNA letter) and splicing. The lead programs are WVE-007, an INHBE-silencing siRNA for obesity; WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD); and WVE-008, an editing program for PNPLA3 I148M liver disease. Older programs in Duchenne (WVE-N531) and Huntington's (WVE-003) are being offered to partners. In August 2026 the company redomiciled from Singapore to Delaware, becoming Wave Life Sciences, Inc.

Full WVE guide

LLY vs WVE: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
  • WVE drivers: WVE-006 and the AATD registrational path; WVE-007 repositioned as a combination and maintenance drug.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For WVE, the central risk is that WVE-007 never produces meaningful weight loss.

LLY or WVE: which should you pick?

If the story you believe is LLY's (GLP-1 obesity and diabetes leadership), LLY is the more direct way to own it; if it is WVE's (WVE-006 and the AATD registrational path), WVE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and WVE guides.

LLY vs WVE: the full fundamentals

LLY. At about $1,353 a share on November 20, 2026, Eli Lilly is valued near $1.2 trillion, roughly 44x trailing earnings and 27x the roughly $50.87 in EPS analysts expect for 2027. That premium rests on revenue growth near 39% in the latest quarter and margins (about 51% operating) that few drugmakers have reached. The debate centers on how large and durable the incretin market proves, how oral therapies such as Foundayo change it, and how Novo Nordisk and new entrants shape pricing; the mean analyst target of about $1,470 sits roughly 9% above the price.

WVE. Wave has no product revenue, so earnings multiples do not apply; the useful lens is enterprise value against pipeline and cash. At ~$2.65 on November 20, 2026, the market cap is ~$524 million, and subtracting ~$431 million of cash leaves ~$93 million for everything else, about 1.3x trailing collaboration revenue and about 1.3 times book value overall. Net loss per share was ~$0.30 in Q3 2026, and analysts expect about -$1.09 for 2026. Analyst targets average ~$16.63, showing that the valuation hinges almost entirely on how WVE-006 and WVE-007 data land.

Headline figures (approximate, November 2026): LLY shows revenue (ttm) ~$86.5 billion, q3 2026 revenue ~$24.4 billion (up ~39% YoY), q3 2026 eps $7.48 vs ~$6.35 est., gross / operating margin (ttm) ~84% / ~51%; WVE shows revenue (ttm) ~$71 million, q3 2026 revenue ~$13.2 million vs ~$9.9 million expected, q3 2026 eps -$0.30 vs ~-$0.32 expected, net loss (ttm) ~-$211 million.

The bottom line: LLY vs WVE

LLY and WVE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined LLY and WVE exposure against your real portfolio. It is not an investment adviser.

Wondering how LLY or WVE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Eli Lilly

Ask Walnut's AI anything about LLY and see how it fits what you own.

FAQ

What is the difference between LLY and WVE?

+

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Wave Life Sciences builds oligonucleotide medicines, short synthetic strands of genetic material that silence, edit or splice RNA inside cells. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is LLY or WVE the better stock?

+

Neither is universally better. LLY is the larger incumbent; WVE is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, LLY or WVE?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both LLY and WVE?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of LLY vs WVE?

+

LLY: LLY trades at a premium valuation (about 44x trailing and 27x forward earnings, and roughly 14x sales, as of November 20, 2026), so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence. The balance sheet has also become more leveraged as Lilly funds capacity: debt was about $49.5 billion against about $4.9 billion of cash at September 30, 2026, and trailing free cash flow of about $9.3 billion is far below operating cash flow of about $30.7 billion because of heavy capital spending. Revenue growth also slowed from about 48% in the second quarter to about 39% in the third as the base gets larger, and GAAP net income fell quarter over quarter, so the pace of growth is now part of the debate. WVE: The central risk is that WVE-007 never produces meaningful weight loss. The Phase 1 data showed body composition changes but little movement on the scale, and the high-BMI Phase 2a and the tirzepatide combination trial may confirm that, which would remove most of the obesity value the market once assigned. WVE-006 must show durable M-AAT levels in larger, longer trials, and competing approaches from Beam Therapeutics and Korro Bio could reach the clinic or market with stronger data. Revenue depends on a single partner, GSK, and its timing is unpredictable, as the ~$2.3 million second quarter showed. Operating expenses rose to ~$79 million a quarter in Q3 2026 and the company has an accumulated deficit of ~$1.48 billion, so further dilution is likely before any product revenue arrives. Law firm Johnson Fistel has advertised an investigation tied to the March 26, 2026 drop, but the October 2026 10-Q states Wave is not party to any material legal proceedings. At ~$2.65 the stock is volatile and sensitive to every data update; it kept falling after the November 2026 ObesityWeek update, which again gave no weight-loss figure.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell LLY or WVE; figures are approximate and dated (as of November 2026). Verify current data before investing.